What is Zacks Research’s Estimate for EW FY2025 Earnings?

Edwards Lifesciences Co. (NYSE:EW) – Analysts at Zacks Research boosted their FY2025 EPS estimates for shares of Edwards Lifesciences in a research note issued on Tuesday, January 7th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $2.44 for the year, up from their previous estimate of $2.43. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share.

Several other analysts also recently issued reports on EW. Robert W. Baird reduced their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Canaccord Genuity Group lifted their price objective on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a report on Thursday, December 5th. Citigroup boosted their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Truist Financial reaffirmed a “hold” rating and issued a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Finally, Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Sixteen research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $79.40.

Edwards Lifesciences Stock Up 0.7 %

Shares of NYSE:EW opened at $74.16 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences has a 52-week low of $58.93 and a 52-week high of $96.12. The business’s 50 day simple moving average is $71.52 and its two-hundred day simple moving average is $72.31. The firm has a market cap of $43.74 billion, a P/E ratio of 10.70, a PEG ratio of 3.61 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.67. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm’s revenue was up 8.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.59 EPS.

Institutional Investors Weigh In On Edwards Lifesciences

Several large investors have recently added to or reduced their stakes in the business. Nordea Investment Management AB boosted its position in shares of Edwards Lifesciences by 34.6% during the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after acquiring an additional 1,043,484 shares during the last quarter. GAMMA Investing LLC raised its stake in Edwards Lifesciences by 16.0% in the fourth quarter. GAMMA Investing LLC now owns 4,761 shares of the medical research company’s stock valued at $352,000 after purchasing an additional 656 shares in the last quarter. Versant Capital Management Inc lifted its position in Edwards Lifesciences by 102.5% during the fourth quarter. Versant Capital Management Inc now owns 1,553 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 786 shares during the last quarter. IMPACTfolio LLC purchased a new position in Edwards Lifesciences in the 4th quarter worth approximately $215,000. Finally, Principal Financial Group Inc. increased its holdings in shares of Edwards Lifesciences by 2.2% in the 3rd quarter. Principal Financial Group Inc. now owns 817,516 shares of the medical research company’s stock worth $53,948,000 after buying an additional 17,647 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 37,500 shares of company stock worth $2,508,350. 1.29% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.